Cortexyme (NASDAQ:CRTX) & Genocea Biosciences (NASDAQ:GNCAQ) Critical Survey
Cortexyme (NASDAQ:CRTX) & Genocea Biosciences (NASDAQ:GNCAQ) Critical Survey
This is a summary of recent recommendations for Cortexyme and Genocea Biosciences, as provided by MarketBeat. Cortexyme (NASDAQ:CRTX – Get Rating) and Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.
Cortexyme(纳斯达克：CRTX-GET评级)和Genocea Biosciences(纳斯达克：GNCAQ-GET评级)都是小盘医疗公司，但哪一家是优势业务？我们将根据这两家公司的股息实力、机构所有权、估值、收益、分析师建议、风险和盈利能力对它们进行比较。
Earnings & Valuation
收益与估值
This table compares Cortexyme and Genocea Biosciences' gross revenue, earnings per share and valuation.
下表比较了Cortex yme和Genocea Biosciences的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cortexyme | N/A | N/A | -$89.94 million | ($2.97) | -0.31 |
| Genocea Biosciences | $1.64 million | 0.01 | -$33.20 million | ($0.61) | 0.00 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 皮质酶 | 不适用 | 不适用 | -8,994万元 | ($2.97) | -0.31 |
| Genocea生物科学 | 164万美元 | 0.01 | -3320万美元 | ($0.61) | 0.00 |
Genocea Biosciences has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Genocea Biosciences的收入和收益比Cortexyme更高。Cortexyme的市盈率低于Genocea Biosciences，这表明它目前是两只股票中更负担得起的一只。
Analyst Ratings
分析师评级
This is a summary of recent recommendations for Cortexyme and Genocea Biosciences, as provided by MarketBeat.
这是由MarketBeat提供的Cortex yme和Genocea Bioscience的最新建议摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cortexyme | 0 | 0 | 1 | 0 | 3.00 |
| Genocea Biosciences | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 皮质酶 | 0 | 0 | 1 | 0 | 3.00 |
| Genocea生物科学 | 0 | 0 | 0 | 0 | 不适用 |
Cortexyme presently has a consensus target price of $15.00, suggesting a potential upside of 1,517.08%. Given Cortexyme's higher probable upside, equities analysts plainly believe Cortexyme is more favorable than Genocea Biosciences.
Cortexyme目前的共识目标价为15.00美元，暗示潜在上行1,517.08%。考虑到Cortexyme更有可能上行，股票分析师显然认为Cortexyme比Genocea Biosciences更有利。
Insider and Institutional Ownership
内部人与机构持股
63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cortexyme 63.2%的股份由机构投资者持有。相比之下，Genocea Biosciences 0.6%的股份由机构投资者持有。Cortexyme 27.9%的股份由内部人士持有。相比之下，Genocea Biosciences 1.6%的股份由内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一家公司有望实现长期增长。
Profitability
盈利能力
This table compares Cortexyme and Genocea Biosciences' net margins, return on equity and return on assets.
此表比较了Cortex yme和Genocea Biosciences的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Cortexyme | N/A | -70.96% | -63.53% |
| Genocea Biosciences | N/A | N/A | N/A |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 皮质酶 | 不适用 | -70.96% | -63.53% |
| Genocea生物科学 | 不适用 | 不适用 | 不适用 |
Volatility and Risk
波动性和风险
Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.
Cortex yme的贝塔系数为1.4，这意味着其股价的波动性比标准普尔500指数高出40%。相比之下，Genocea Biosciences的贝塔系数为1.99，这意味着其股价的波动性比标准普尔500指数高99%。
Summary
摘要
Genocea Biosciences beats Cortexyme on 6 of the 10 factors compared between the two stocks.
Genocea Biosciences在两只股票之间的10个因素中有6个击败了Cortexyme。
About Cortexyme
关于Cortex yme
(Get Rating)
(获取评级)
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Cortexyme，Inc.是一家临床阶段的生物制药公司，专注于开发阿尔茨海默氏症和其他退行性疾病的疗法。它的主要候选药物是ATuzaginstat(COR388)，这是一种口服的脑穿透性小分子牙龈痛抑制剂，正处于II/III期临床试验，用于轻至中度阿尔茨海默病患者，以及用于治疗口腔鳞状细胞癌、牙周炎和冠状病毒感染。该公司成立于2012年，总部位于加利福尼亚州旧金山南部。
About Genocea Biosciences
关于Genocea生物科学
(Get Rating)
(获取评级)
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Genocea生物科学公司致力于癌症免疫疗法的开发和商业化。该公司使用其专有技术平台ATLAS，根据实际的人类免疫反应识别临床相关的T细胞抗原。它的候选产品包括研究采用T细胞疗法的Gen-011和新抗原癌症疫苗Gen-009。该公司由Robert Paull和Kevin J.Bitterman于2006年8月16日创立，总部设在马萨诸塞州剑桥市。
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cortexyme Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收对Cortexyme和相关公司的最新新闻和分析师评级的每日简要摘要。